As always, however, there are some challenges associated with trying to promote goals of this kind. A big problem for member states is brain drain. Research policy limitations that impact member states’ ability to establish international collaboration in technology transfer are yet another dilemma.
There is also a considerable lack of strong management in large-scale research policy and strategic planning. The researcher’s work is controlled by the granting agency and can be changed accordingly. If money is allocated to a particular subject, the researcher has to follow, with less attention to what may be actually considered the national priorities.
In addition, the potential of genomics and biotechnology for national growth has not yet been fully realized and therefore political support is lacking. Financial investments are also small and capacities, both human and material, are fragile.
Developing nations around the world face similar challenges, of these, the lack of communication and coordination between scientists to share knowledge and experience is the most visible. Thus scientific interaction and exchange in genomics and biotechnology needs to be strengthened.
While ties between nations must be strengthened, the partners within the network need to understand the benefits of being a member of the network.
The network should do more than just connect member states in the region. It should be able to govern and supervise projects, based on regional demands and priorities. EMHGBN should also be the sole organizer of all activities within member states.
The expectations of developed countries in this endeavor can be categorized into three main areas, providing finance, transfer of technology, and experience. The much renowned expertise in the industrialized world can be a big help. At the same time, it is important that the EMHGBN functions independently of the influence of governments and international organizations, such as WHO. It should have its own mandate and system of governance.